Symptoms of hematologic malignancies are usually mild or inconspicuous, leading to delays in diagnosis and treatment of indications.BCL-2 (B-cell lymphoma 2) inhibitors regulates the correlation of cell apoptosis at the mitochondrial level, which has the potential to be a therapeutic target for hematologic malignancies.
This report contains market size and forecasts of BCL-2 (B-cell lymphoma 2) Inhibitors in Global, including the following market information:
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global BCL-2 (B-cell lymphoma 2) Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Combination Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of BCL-2 (B-cell lymphoma 2) Inhibitors include AbbVie, Roche, Abcam, Biorbyt, Biovison and Tocris Bioscience, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the BCL-2 (B-cell lymphoma 2) Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Segment Percentages, by Type, 2021 (%)
Combination Therapy
Monotherapy
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Segment Percentages, by Application, 2021 (%)
Positive Lymphoma
Follicular Lymphoma
Others
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies BCL-2 (B-cell lymphoma 2) Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies BCL-2 (B-cell lymphoma 2) Inhibitors revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Roche
Abcam
Biorbyt
Biovison
Tocris Bioscience